full announcement

08 Jul 2019 14:34 CET

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 8 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019. 

Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.

Since the announcement as of 1 July 2019, the following transactions have been made under the programme:


 Number of

B shares

purchase price

value, DKK
Accumulated, last announcement4,468,000 1,464,295,863
1 July 2019125,000339.3142,413,255
2 July 2019128,000342.9143,892,487
3 July 2019140,500346.8848,736,153
4 July 2019135,900342.5446,551,012
5 July 2019125,000339.8042,474,713
Accumulated under the programme5,122,400 1,688,363,483


The details for each transaction made under the share repurchase programme are published on

With the transactions stated above, Novo Nordisk owns a total of 27,465,543 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 5 July 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 20,298,904 B shares at an average share price of DKK 326.29 per B share equal to a transaction value of DKK 6,623,317,084.

Further information

Anne Margrethe Hauge+45 4442
Ken Inchausti (US)+1 609 240
Peter Hugreffe Ankersen+45 3075
Valdemar Borum Svarrer+45 3079
Ann Søndermølle Rendbæk+45 3075
Kristoffer Due Berg (US)+1 609 235

Company announcement 40/2019